Melissa Badamo

Articles by Melissa Badamo

Melissa BadamoMyelodysplastic Syndromes | November 22, 2024
High circular RNA abundance is correlated with disease progression in patients with MDS.
Melissa BadamoAcute Lymphoblastic Leukemia | November 21, 2024
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
Melissa BadamoMyelodysplastic Syndromes | November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Melissa BadamoAcute Myeloid Leukemia | November 19, 2024
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
Melissa BadamoMyelodysplastic Syndromes | November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Melissa BadamoMyelodysplastic Syndromes | November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
This issue of Blood Cancers Today includes a feature on MRD updates; a Get to Know with Matthew Lunning, DO, FACP; and more.
Melissa BadamoPrint | November 15, 2024
Since 1974, Dr. Steven Rosenberg has served as Chief of the Surgery Branch at the NCI.
Melissa BadamoPrint | November 22, 2024
Dr. Lunning discusses his origins in clinical research, the rise of cellular therapy, and more.
Melissa BadamoPrint | November 15, 2024
The IMS presented annual awards to three multiple myeloma clinicians and researchers during the 21st Annual Meeting.
Melissa BadamoMyeloma | November 14, 2024
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Melissa BadamoMyeloma | November 14, 2024
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Melissa BadamoMyeloma | November 14, 2024
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Melissa BadamoMyeloma | November 14, 2024
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Melissa BadamoMyelodysplastic Syndromes | November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
Melissa BadamoAcute Myeloid Leukemia | November 6, 2024
Researchers have validated a new molecular prognostic risk signature for patients with AML who received HMAs and venetoclax.
Melissa BadamoMyelofibrosis | November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Melissa BadamoMyelofibrosis | November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.